尾盘突变！13倍大牛股巨震

Core Viewpoint - The stock of Yaojie Ankang-B experienced extreme volatility on September 16, initially surging over 60% before plummeting to a closing loss of 53.73%, resulting in a market capitalization drop from 245.7 billion HKD to 76.2 billion HKD [1][7]. Group 1: Stock Performance - On September 16, Yaojie Ankang-B's stock price rose over 60% in the morning, reaching 619 HKD per share, with a market cap of 245.7 billion HKD, surpassing other notable biotech firms [1]. - The stock then faced a dramatic decline, closing at 192 HKD per share, marking a 53.73% drop and a market cap reduction to 76.2 billion HKD [1][7]. - Since its listing on June 23, Yaojie Ankang-B's stock has seen a cumulative increase of over 13 times, with significant daily gains of 77% and 116% on September 12 and 15, respectively [4][10]. Group 2: Company Background and Financials - Yaojie Ankang-B is a biopharmaceutical company focused on developing innovative therapies for oncology, inflammation, and cardiovascular metabolic diseases, currently in the clinical trial phase [4]. - The company reported a combined loss exceeding 600 million RMB for 2023 and 2024, with losses of 343 million RMB and 275 million RMB for each respective year [3][6]. - As of September 15, the top 10 brokerage firms held 99.82% of the shares, indicating a high concentration of ownership and limited market liquidity [3][9]. Group 3: Market Dynamics - The stock's volatility is attributed to its small float, with a significant portion of shares held by major stakeholders, including the founder, who owns 32.98% [9]. - The recent surge in stock price is linked to its inclusion in the Hong Kong Stock Connect on September 8, which has attracted significant investment from the program [10]. - The lack of short-selling options in the market exacerbates price movements, making the stock susceptible to rapid increases and subsequent declines [9].